Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bactiguard, Audiocast, Q2'26

By Inderes7/14/2026, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christine Lind
00:00 - 07:39

Thank you, operator, and a warm welcome to everyone joining us for Bactiguard's second quarter presentation for 2026. I'm joined today by our CFO, Patrick Bach. And I'll take you through the quarter's strategic highlights, and then hand over to Patrick for a closer look at the numbers before we open the line up for your questions. Today's title, "Solid performance driven by revenue growth," captures exactly where we landed this quarter. Strong top-line momentum across the business, confirming that the slower start to the year was simply a matter of timing rather than any change in trend. So let's dive straight into the quarter and start with the numbers. We're pleased to report second quarter net sales growth, excluding currency, of 16%. The main driver was a recovery in BD revenues alongside one of the strongest quarters our Wound Management portfolio has ever recorded. This quarter confirms that the softer start to the year was a matter of timing, not a change in trend, as I said, and our strategy execution is on track. Adjusted EBITDA came in at 5.6 MSEK, up from 4.4 MSEK a year ago, lifted by sales growth and continued cost discipline. It's a good illustration of how top-line growth flows through to earnings in a scalable, license-based business, and it gives us room to keep investing in future growth. Cash flow from operations amounted to 12.4 MSEK, a clear step up from the 1.7 MSEK in the same quarter last year. Strategically, it was an eventful quarter. Second, we signed a new long-term agreement that deepens our already 35-year partnership with BD. We are seeing growth in the number of patients using Bactiguard-coated implants with Zimmer Biomet, and we had strong momentum in our early partner dialogues. Let me take you through these one at a time. Let's turn to BD. In May, we announced a new long-term agreement with BD, deepening a partnership that goes back to 1990, more than 35 years. Few things illustrate the long-term value that our coating technology creates for partners better than this, or how embedded Bactiguard-coated products become in patient care. Once adopted, what started as a collaboration covering select markets has steadily grown into a true global partnership. Today, it spans the full value chain from technology development to global market execution and is focused on expanding adoption of our infection prevention technology. The restated agreement modernizes the partnership terms and strengthens that foundation further. It builds on the December 2023 extension under which BD was granted worldwide exclusivity for Bactiguard-coated Foley catheters outside of China. Alongside the commercial terms, a key part of the agreement has been aligning on the regulatory approvals needed to support smooth market transitions, something that's been a shared focus with BD over the past two years, and that has now enabled recent launches in the Nordics, Poland, and parts of the Middle East. We have backed each of these commercialization initiatives with technology training across the regions, and we continue to transition our KOL relationships and former customers to support market access and commercial execution for BD. As I said when we announced the agreement back in May, this is a great example of the power and potential of our license-focused strategy, a partnership that's globally growing and built on shared success. In the quarter, BD revenues came in 50% above the weak second quarter of last year and are also up 8% so far this year, reaching 28.2 MSEK on a reported basis, as in prior quarters. BD revenues are shaped by the timing of concentrate shipments into their supply chain, which can create variation from one quarter to the next. But we continue to see underlying growth both from existing and new markets. Now to Zimmer Biomet, our partnership continues to focus on driving commercial adoption. Bactiguard is leading the work to transition the trauma implants to the MDR regulatory requirements in Europe and supporting the post-market clinical studies. We are very pleased to note that the first of the ongoing multicenter studies is now complete, which is an encouraging step, and the key comparative study is progressing according to plan. We are especially pleased to see growing use of Bactiguard-coated implants in patients. There is still meaningful headroom here, given how small a share of the total trauma market coated implants represent today. Overall, we see the partnership as financially stable, with revenues of 3.8 MSEK in the quarter in line with our expectations, double-digit growth in product sales and clear long-term potential as adoption continues to build. Let's turn to business development. We spent a good part of the quarter on new business development, meeting potential future partners at conferences and in direct discussions across the US and Europe. Since launching our five focused therapeutic areas back in March of 2025, we have now completed a full annual calendar of conferences across all of them where we focus on business development activities. The need to find infection prevention solutions is especially recognized in orthopedics, and it is clear that the strongest engagement with Bactiguard is here. We are also able to capitalize on this category by having rights in various orthopedic segments available for licensing. Since amending our agreement with Zimmer Biomet at the end of 2025, we remain focused on advancing these discussions with potential partners while recognizing that in a licensed business, dialogues like these can take time to mature into signed agreements. We remain focused on advancing these discussions with potential partners while recognizing that in a licensed business, dialogues like these can take time to mature into signed agreements. Now to Wound Management, which had a standout quarter; the portfolio delivered very strong performance indeed, with 67% revenue growth for the quarter and 25% over the first six months. Our flagship Hydrocyn aqua line led the way, supported by stabilization in sutures, with growth in the portfolio across the Middle East, Europe, and Asia. Tender business in select regions also gave a positive boost in the quarter. Alongside the strong commercial execution, we continue to strengthen the product portfolio, invest in the availability of products in new markets and build out our operational setup in Malaysia. As we've said before, we continue to expect double-digit growth from the combined Wound Management portfolio, fueled by high double-digit growth from Hydrocyn aqua and a stable contribution from sutures. And this quarter confirms that we continue to be on track with that. Over to Patrick for a closer look at the numbers.

Patrick Bach
07:41 - 11:57

Thank you. Thank you, Christine. We are very happy to present solid growth for Q2. We report both revenue growth, continued profitability, increased cash generation, and we see positive momentum across the business. Total revenue came in at 57 MSEK, up from 52 MSEK. Total revenues grew 12%. Net sales grew 16%, excluding currency effects. I said this is driven by strong growth in BD revenues and a very strong quarter from our Wound Management portfolio. In fact, this was the strongest quarter and the strongest revenues on a rolling 12-month basis ever. Looking closer at our core license business, we see license revenues lifted by the strong growth in BD, which came at 28.2 MSEK. This is up 50% versus a weak second quarter last year, but up 8% versus the first half of last year. And as said, we see strong continued underlying momentum in the BD business and the BD partnership. Zimmer Biomet contributed with approximately 4 MSEK in the quarter, in line with our expectations and reflecting historical trends. A double-digit growth in the sales of the Zimmer Biomet Bactiguard-coated nails. The reason for the decline in the total license revenues is found in the high comparable base from last year, in which Q2 included a full year of minimum royalties from the previous agreement. As communicated, fixed fees in our new agreement will be consistent across the quarters going forward. Across both partnerships, we continue to see positive in-market volume growth, and we are excited to see the future demand from customers and clinicians for our technology, which underpins and adds to the risk reduction efforts healthcare professionals must deal with on a daily basis. On OPEX, we remained cost-conscious and maintained cost discipline during the quarter, while also investing selectively to support growth. This includes, for example, our regulatory capabilities, business development activities, as well as strengthening our teams and operations globally, including in our Malaysian business. For the quarter, we did see an increase of total OPEX of 11%, while the half-year period holds about a 1.5% total increase in OPEX. The Q2 increase mainly pertains to timing effects on bonus accruals, which were reversed in Q1 2026 versus Q2 last year in 2025, i.e. A lower comparable for Q2. As communicated previously, we will continue to operate with cost discipline while ensuring the right investments in growth. On Adj. EBITDA, we came in close to 6 MSEK for the quarter, up from 4.4 MSEK in Q2 last year, driven by sales growth. And as I said, continued cost discipline. Our margin on adjusted EBITDA increased to 10% for the quarter, as well as approximately 10% for the first six-month period. Net profit for the quarter was -8.2 MSEK, in line with the -8.1 MSEK in Q2 last year. On cash flow, we see cash flow from operating activities amounted to a bit more than 12 MSEK for the quarter, a substantial improvement of more than 10 MSEK versus the 1.7 MSEK in Q2 last year. Also, total cash flow for the period was positive at 7.4 MSEK, and our total cash and cash equivalents at the quarter end amounted to 43.5 MSEK, up from approximately 35 MSEK at the end of Q1. So with that, back to you, Christine.

Christine Lind
12:02 - 13:35

Thank you. Patrick. With growth across all of our businesses, including double-digit increase in Wound Management, our focus now is on converting these investments into sustained traction. We are on the right track and we will keep executing towards our strategic targets. I want to be clear that nothing about the previous quarter changes our strategic direction or the fundamentals of the business. Our targets for 2030 stand unchanged. We remain focused on strengthening our partnerships, continuing to invest in our key knowledge areas that help advance our partners through regulatory approvals and to commercialization and building long-term value through disciplined execution across the portfolio. To sum up, this was a quarter of broad-based growth with net sales up 16% and further improvements in both Adj. EBITDA and cash flow. We renewed and deepened our 35-year partnership with BD, and we continue to see growing momentum with Zimmer Biomet, with double-digit growth in product sales as coated implant use in patients builds; Wound Management delivered one of the strongest quarters ever, up 67%. And we have a strong partnership pipeline building, particularly in orthopedics. Taken together, we remain firmly on track with that. Let's open up for questions.

Operator
13:37 - 13:55

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Maria Karlsson from DNB Carnegie. Please go ahead.

Maria Karlsson
13:58 - 14:24

Hi, Christine and Patrick. Are you there from Carnegie? Thanks for taking my questions. Great. So congratulations on that as well. I have some questions. However, on the COGS level. Historically, we have seen some lumpy gross profits and we see COGS increasing this quarter. How should we think about the gross margin profile going forward? I mean this is mostly a portfolio effect, but still, what should we expect going forward?

Patrick Bach
14:27 - 15:11

Yeah. Thank you, Maria, for your question. You are absolutely right. We have historically seen a somewhat lumpy COGS profile. We obviously try to have it less lumpy going forward. I think what we see in Q2 is not the same picture you will see going forward. Part of what drives the Q2 is product mix. We saw a higher volume of sales in Wound Management, obviously with the high growth in that segment. And we have also had some additional scrapping in Q2. So going forward, I think you can assume the level that we have seen consistently in the past periods.

Maria Karlsson
15:14 - 15:29

All right. Thank you. And talking about Wound Management, is this high growth repeatable? I mean you mentioned high double-digit growth there. And you also mentioned a positive boost from the tender business. Is there any proportion that you can talk to us about?

Patrick Bach
15:31 - 16:54

I think, in short, we would love if we continue to report 50% to 60% growth for Wound Management. But that, I think, is certainly not our expectation for the business. As we have said before, we have a confident long-term view on the business to deliver sustained double-digit growth that includes both the Hydrocyn aqua part of the business and the sutures business combined. As we have said before, we see the sutures business more as a stable business. Whereas in our portfolio, we see continued high double-digit growth, which we expect going forward. I think with this quarter, we have continuous confirmation that we see positive demand by customers, obviously from our distributors, of the portfolio. And as we have said, we have seen a stabilization of the sutures business this year, which affected us a bit last year. So we have a continued positive view on the growth coming from our Malaysian-based Wound Management business. As we've talked about before, we see growth across the regions, notably from the Middle Eastern region, from Europe, as well as our legacy markets in Asia.

Maria Karlsson
16:57 - 17:19

All right. And just a little more focus on costs. The MDR spend. Have you guided previously on what you expect the total MDR expenses to be? What should we expect in the second half of the year and maybe some timelines? How long are you planning to carry out the work with the MDR? Carry on the work with the MDR?

Patrick Bach
17:20 - 18:41

Yeah. I appreciate the question. I think in short, we have not provided guidance regarding that for the full year. We have an increased amount of non-recurring costs this year that we can single out that relate to MDR. This is what we highlight in the report. We have highlighted in the adjusted EBITDA the impact related to MDR costs. We have highlighted that we see this potential in 2026 and 2027. I believe that we will see more cost and the majority of the cost in 2026 versus 2027. We are halfway through the year, but we don't have specific guidance on the total costs; however, we will obviously continue to incur MDR-related costs that we consider non-recurring in the remaining Q3 and Q4 of this year. In addition to these regulatory costs, we have normal regulatory costs in our business, which we obviously do not single out. But we will continue to report these MDR-related non-recurring costs in the report for Q3 and Q4 as well.

Christine Lind
18:41 - 19:15

And Maria, this is Christine. From a qualitative standpoint, we can also comment that with BD, the underlying Foley product portfolio has already been upgraded to the MDR regulatory guidelines so that that product portfolio is complete from an MDR standpoint and is approved and is currently regulated under MDR, and we are currently working on both the transitions of the Zimmer Biomet trauma implants, as well as our wound management portfolio, all of which are, of course, device-related under the MDR regulations.

Maria Karlsson
19:18 - 19:24

All right. Thank you for the addition there. That was all my questions. Thank you very much. And yet again, congrats on the good quarter.

Unknown 1
19:25 - 19:26

Thank you. Thank you.

Operator
19:26 - 19:30

The next question comes from Matthias Madsen from CIB. Please go ahead.

Matthias Madsen
19:33 - 20:07

Hi. Thanks for taking my questions. I think it was good to see the revenues normalizing this quarter. Quite a good step up from Q1. I just want to ask if you would say this represents the sort of run rate you are at right now, with no specific items either helping or weighing it down. And if we are likely to see lower volatility in the revenue line going forward, or if the volatility will still be there based on your understanding.

Patrick Bach
20:09 - 22:07

Yes. Thank you, Matthias, for your question. We are of course also very happy to be able to report numbers that I think sustain what we have communicated as a very solid and positively underlying growing partnership and momentum for BD. What we have stated, and obviously what we've talked about in the past quarters, is that we did see an effect of some of the delayed registrations in Europe. We believe, and we of course work as much as we can to ensure that there will be less volatility going forward. So that is what we expect. That is what we hope. That is what we focus on. Matthias. What you see in Q2 for this quarter is obviously more similar to Q3 and Q4 of the last year, which were, as we also reported, more normal quarters. So I believe, yes, in short, this is about the level that we are very happy to see from BD and from there on, of course, we still continue and expect to grow. We do expect less volatility going forward, but of course, it is sometimes out of our hands, and we are not able to guide fully on this; however, as we said before, we see continued positive underlying growth in the BD business with mid-single-digit volume growth in the markets. And as Christine also communicated, we see a positive response from many new geographies, already preparing to have products available with Bactiguard-coated Foley catheters in these markets.

Matthias Madsen
22:10 - 22:24

I think that's a very clear answer. The next question relating to BD would be what share of the revenues there comes from new markets outside the US, Japan, etc. . Do you have that level of insights?

Patrick Bach
22:28 - 22:41

Thanks for your question, Matthias. Just to understand, what share of revenue is in the new markets that they will potentially or have launched in versus the existing markets?

Matthias Madsen
22:42 - 22:50

Yes, such as India and Europe, which were added to the agreement you had before.

Patrick Bach
22:52 - 24:18

I mean, in short, we do not have the split on these markets. And I think in fact, which is what obviously we and BD are trying to do together, is not to necessarily capture market share from existing other coated catheters. This rarely exists, but we aim to build the markets. We know today that obviously the existing markets, with the US being the biggest, have the biggest potential. So of course, we're trying to build a lot of additional markets that in size will not obviously be bigger than the existing business and it will take time, but this is the work that we are committed to and that BD is committed to. We see very positive response from these markets that have not had Bactiguard-coated Foley catheters available before. We see positive response from their sales teams, as they would like to offer this to their customers and to the patients ultimately. So we believe that the additional markets that we have now under the new global agreement will definitely sustain positive growth for BD going forward. But obviously, for the foreseeable future, it will still be a lesser portion of the total revenue base versus the existing markets.

Matthias Madsen
24:21 - 24:24

Thank you very much. Those were the questions I had today.

Patrick Bach
24:26 - 24:27

Thank you, Matthias.

Operator
24:27 - 24:34

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Christine Lind
24:39 - 24:55

Thank you. Operator. Thank you for all your questions and for your continued interest in Bactiguard. We appreciate the dialogue and look forward to updating you at our next available opportunity. And with that, back to you, operator, for closing out the call.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…